https://www.natcopharma.ca/fr/natco-receives-final-approval-for-everolimus-tablets-generic-for-zortress9-in-the-us-market/ 2021-09-03T10:19:09+00:00 https://www.natcopharma.ca/fr/natco-launches-nat-abiraterone-tablets-250mg-in-canada/ 2021-09-03T10:20:29+00:00 https://www.natcopharma.ca/fr/natco-pharma-canada-inc-announces-the-launch-of-prnat-lenalidomide-capsules-the-first-generic-alternative-to-revlimid/ 2021-09-03T13:35:15+00:00 https://www.natcopharma.ca/fr/natco-launches-nat-bendamustine-powder-for-suspension-25mg-and-100mg-in-canada/ 2021-09-03T13:35:42+00:00 https://www.natcopharma.ca/fr/natco-transfers-lenalidomide-anda-to-arrow/ 2021-09-03T13:37:16+00:00 https://www.natcopharma.ca/fr/natco-receives-approval-for-carfilzomib-vials-anda-generic-for-kyprolis-in-the-us-market/ 2021-09-03T13:37:30+00:00 https://www.natcopharma.ca/fr/natco-receives-tentative-approval-for-ibrutinib-tablets-generic-for-imbruvica-anda-in-the-us-market/ 2021-09-03T13:37:43+00:00 https://www.natcopharma.ca/fr/natco-receives-usfda-approval-for-lenalidomide-capsules/ 2021-09-03T13:37:49+00:00 https://www.natcopharma.ca/fr/natco-starts-phase-iii-clinical-trial-of-molnupiravir-capsules-for-covid-19-treatment/ 2021-09-03T13:37:55+00:00 https://www.natcopharma.ca/fr/natco-signs-voluntary-licensing-agreement-with-lilly-for-baricitinib-for-covid-19-in-india/ 2021-09-03T13:38:03+00:00 https://www.natcopharma.ca/fr/natco-receives-emergency-use-approval-for-baricitinib-tablets-for-covid-19-treatment/ 2021-09-03T13:38:10+00:00 https://www.natcopharma.ca/fr/natco-seeks-emergency-approval-of-molnupiravir-capsules-for-covid-19-treatment/ 2021-09-03T13:38:30+00:00 https://www.natcopharma.ca/fr/natco-receives-final-approval-for-everolimus-tablets-generic-for-afinitor-for-the-us-market/ 2021-09-03T13:38:44+00:00 https://www.natcopharma.ca/fr/natco-launches-brivaracetam-tablets-in-india-for-treatment-of-epilepsy/ 2021-09-03T13:38:58+00:00 https://www.natcopharma.ca/fr/natco-announces-launch-of-its-10mg-strength-for-everolimus-tablets-generic-for-afinitor-in-the-us-market/ 2022-01-06T21:00:59+00:00 https://www.natcopharma.ca/fr/natco-launches-tipanat-tablets-in-india-for-the-treatment-of-advanced-colorectal-and-gastric-cancer/ 2022-01-06T21:02:28+00:00 https://www.natcopharma.ca/fr/natco-proposes-to-acquire-dash-pharmaceuticals-llc/ 2022-01-06T21:04:03+00:00 https://www.natcopharma.ca/fr/natco-receives-approval-for-the-a-drug-for-the-treatment-of-covid-19-in-india/ 2022-01-06T21:06:56+00:00 https://www.natcopharma.ca/fr/natco-completes-acquisition-of-dash-pharmaceuticals-llc/ 2022-01-06T21:08:08+00:00 https://www.natcopharma.ca/fr/natco-canada-launches-nat-teriflunomide-tablets/ 2022-05-16T17:39:08+00:00 https://www.natcopharma.ca/fr/natco-canada-launches-nat-apixaban-tablets/ 2022-09-21T02:01:46+00:00 https://www.natcopharma.ca/fr/natco-pharma-canada-inc-announces-the-launch-of-nat-pomalidomide-capsules-the-first-generic-alternative-to-pomalyst-in-canada/ 2023-02-28T14:10:12+00:00 https://www.natcopharma.ca/fr/natco-canada-launches-nat-everolimus-tablets/ 2023-04-06T18:15:12+00:00 https://www.natcopharma.ca/fr/natco-canada-launches-nat-eribulin/ 2024-01-08T17:01:43+00:00